Cass Entrepreneurship Fund has returned to back a $3.9m funding round for Raremark, which is working on delivering precision medicine for patients suffering from rare diseases.

Drug developers Sanofi and Hikma both contributed to a funding round for health management app developer Click Therapeutics to bring its total financing to more than $26m.

Johnson & Johnson was among the investors in a $54.5m series A round for CuraSen Therapeutics, which is commercialising research from Stanford University.

The cancer therapy developer has raised $80m in a mezzanine round that came almost 18 months after its series C, with Lilly Asia Ventures and SR One backing both rounds.

Endocyte emerged out of Purdue University in 1996, completed an initial public offering in 2011 and has now agreed to an acquisition by Novartis worth $2.1bn.

Warp Drive Bio, the genomic medicine developer co-founded by Sanofi, has agreed to an all-share acquisition by Revolution Medicines.

Johnson & Johnson Innovation – JJDC was among the investors in CuraSen Therapeutics' $54.5m series A round, which was led by New Leaf Venture Partners.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The Novo-backed surgical implant provider floated at the top of its range and increased the number of shares in the offering.

Amgen has invested $66m in genetic sequencing system provider Oxford Nanopore, increasing its latest funding round to $206m.